Introduction: It is hypothesized that cerebral hypoperfusion promotes the development of Alzheimer pathology. We therefore studied whether longstanding cerebral hypoperfusion is associated with Alzheimer pathology in nondemented humans. 
Background
Alzheimer's disease (AD) is the most common cause of dementia, with a prevalence of 5-6% in the population older than 60 years in Western Europe and North America [1] . AD is neuropathologically characterized by the presence of b-amyloid plaques and tau-containing neurofibrillary tangles [2] . b-amyloid accumulation is believed to be the crucial mechanism in AD, starting decades before clinical symptoms, and the presence of b-amyloid seems to be a prerequisite for the spread of tau outside the transentorhinal/entorhinal cortex [3] [4] [5] . Despite large research efforts to understand the mechanisms triggering b-amyloid accumulation in sporadic AD, the cause remains elusive.
Animal models have suggested a role for vascular pathology and cerebral hypoperfusion in the development of b-amyloid pathology [6] [7] [8] [9] . A transient bilateral occlusion of the common carotid arteries in rats induces a nuclear translocation of HIF1a (hypoxia inducible factor1a), thereby increasing the expression of the b-secretase 1 enzyme. b-secretase 1 in turn increases the conversion of the amyloid precursor protein to b-amyloid [6, 10] . In humans, there is a clear reduction of cerebral perfusion in affected regions in patients with manifest AD and mild cognitive impairment due to AD [11] [12] [13] . Moreover, postmortem tissue from AD patients shows evidence of hypoxia-induced alterations in protein expression in areas with b-amyloid pathology [14, 15] . These findings has led to the hypothesis that vascular pathology and hypoperfusion might precede b-amyloid accumulation in AD [9, 16, 17] , but whether they actually represent a cause or a downstream effect is not known, and data from human subjects are lacking.
To examine whether cerebral hypoperfusion increases b-amyloid deposition in humans, we studied a group of patients (n 5 11) with longstanding unilateral internal carotid artery (ICA) occlusion or middle cerebral artery (MCA) stenosis, resulting in uneven perfusion of the cerebral hemispheres. We hypothesized that the hypoperfusion would lead to a unilateral increased deposition of b-amyloid fibrils as visualized with b-amyloid positron emission tomography (PET) imaging. A subset of patients also underwent 18 F-AV-1451 PET scans.
Methods

Participants with unilateral ICA occlusion or MCA stenosis
Patients with a diagnosis of stenosis or occlusion of precerebral arteries, seen at the Department of Neurology, Sk ane University Hospital, Sweden, January 2012-May 2014, were assessed for participation in the study. Inclusion criteria were occlusion or near-occlusion (noncontinuous blood flow) of one of the ICA or a significant stenosis of one of the MCA resulting in a unilateral decrease in cerebral perfusion. Exclusion criteria were major psychiatric disease, neurological disease other than transient ischemic attack or stroke, major stroke in the affected hemisphere, and dementia or major somatic illness. Nineteen patients met the inclusion criteria and were asked to participate in the study. Twelve patients agreed to participate, and eleven patients completed the study. All patients received oral and written information about the study and signed an informed consent form before being enrolled. All procedures were conforming to the Declaration of Helsinki and were reviewed and approved by the regional Ethical Committee at Lund University and the Radiation Protection Committee at Sk ane University Hospital.
Patients underwent neurological and clinical examination, assessment of previous and concomitant diseases, and medication. Patients were tested at the baseline visit using Mini-Mental State Examination and Hospital Anxiety and Depression Scale [18, 19] . Neuropsychological testing was performed at a separate visit and included the Boston Naming Test [20] (verbal naming), Rey Auditory Verbal Learning Test [21] (verbal memory), Brief-Visuospatial Memory Test-Revised [22] (spatial memory), Digit span from the Wechsler Adult Intelligence Scale-IV (working memory/attention), Verbal fluency from the Delis-Kaplan Executive Function System (verbal/mental speed), and Trail making test from the Delis-Kaplan Executive Function System (psychomotor speed/simultaneous attention).
Image acquisition
Magnetic resonance imaging/computed tomography
The patients underwent an extended magnetic resonance imaging (MRI) scan on a 3T scanner (Siemens Skyra, Munich, Germany), comprising contrast-enhanced MR angiography and T2*-weighted MR perfusion as well as high-resolution T1 (magnetization-prepared rapid gradient echo) and fluid-attenuated inversion recovery sequences. Sequence details are provided in the supplementary information (Supplementary Material). Due to contraindications to MRI, two patients underwent plain-computed tomography (CT), CT angiography, and CT perfusion on a Philips Brilliance 64 CT scanner (Philips, Best, the Netherlands) according to routine clinical protocols. In one patient, with reduced renal function, ICA occlusion was verified using Doppler ultrasonography on a Philips iU22 ultrasound system.
PET
18 F-Flutemetamol was obtained from General Electric (GE, Risø, Denmark), and the scanning procedures have been described previously [23] . In brief, the patients received 196 6 2 MBq 18 F-Flutemetamol via an intravenous injection in the antecubital vein. On a separate day, a subset (n 5 5) of the patients received an average of 372 6 2 MBq 18 F-AV-1451. The radiosynthesis of AV-1451 has been described previously [24] . The PET data were acquired on a Philips Gemini TF PET-CT scanner as 4 ! 5 minute dynamic time frames, 80-100 minutes postinjection.
Image analysis
Maps of the mean transit time (MTT) and relative cerebral blood flow (rCBF
Q5
) were calculated from MR data using nordicICE (NordicNeuroLab, Bergen, Norway) and from CT data using software provided by the manufacturer. The presence of infarctions and the degree of stenosis or occlusion in the cervical and cerebral arteries were assessed.
PET data analysis was performed using Pmod 3.603 (Pmod technologies, Zurich, Switzerland). PET images were imported along with high-resolution T1, rCBF, and MTT images. T1 images were segmented into gray and white matter and coregistered to the PET data using the NeuroTool. The brains were segmented using the Automated Anatomical Labeling-atlas, and the cerebellar gray matter regions excluding the vermis were pooled into a composite reference region. Using rCBF, MTT, and magnetizationprepared rapid gradient echo images, areas with hypoperfusion without visible cerebral infarctions on structural sequences were identified. In the area with the most pronounced perfusion changes, one 15-mm diameter spherical hypoperfused volume of interest (VOI) per subject was created. The hypoperfused VOI was then mirrored onto the contralateral (control) hemisphere and intersected using the gray/white matter segmentation mask into VOIs consisting of hypoperfused and more normally perfused cortex and white matter. VOIs were created in the MRI images by a person blinded to the PET data. The rCBF and MTT maps from MRI and PET images were coregistered to the T1 using the Fusion tool. The VOIs were 110  111  112  113  114  115  116  117  118  119  120  121  122  123  124  125  126  127  128  129  130  131  132  133  134  135  136  137  138  139  140  141  142  143  144  145  146  147  148  149  150  151  152  153  154  155  156  157  158  159  160  161  162  163  164  165  166  167  168  169  170  171  172  173  174  175  176   177  178  179  180  181  182  183  184  185  186  187  188  189  190  191  192  193  194  195  196  197  198  199  200  201  202  203  204  205  206  207  208  209  210  211  212  213  214  215  216  217  218  219  220  221  222  223  224  225  226  227  228  229  230  231  232  233  234  235  236  237  238  239  240  241  242  243 18 F-AV-1451 standardized uptake value ratio (SUVRs). SUVR values were calculated using cerebellar composite gray matter as the reference region. In the two cases were an MRI scan was missing, the VOIs were delineated on a CT scan fused to the PET image, and areas of hypoperfusion were assessed using data from CT perfusion maps. 18 F-Flutemetamol uptake in the brain was also measured in a neocortical composite VOI [23] using NeuroMarq (GE Healthcare) to determine amyloid positivity. A previously established cutoff of .1.42 SUVR was used for abnormal b-amyloid uptake [23] . As an additional measure, a larger composite region was created in medial cerebral arteryperfused territory (described in detail the supplementary methods [Supplementary Material]).
Statistics
Statistical analyses were performed using GraphPad Prism 7 for Macintosh or IBM SPSS Statistics for Macintosh, version 23. For assessing differences between hypoperfused and contralateral normally perfused areas, Wilcoxon's signed-rank test was used. Correlations were assessed using Spearman correlations. Statistical significance was considered being P , .05.
Results
Participants
The clinical characteristics of the study participants are described in Table 1 . All 11 subjects were nondemented and had a median age of 69 years (range 51-83 years). They had a unilateral near-occlusion or occlusion in the ICA or a significant unilateral stenosis in the MCA resulting in a regionally reduced cerebral perfusion. The median time of known artery occlusion was 22 months (range 9-258 months) ( Table 1 ). The pathogenesis for arterial occlusion was atherosclerotic disease in all cases but one, who received radiation therapy against a tonsillary adenocarcinoma a decade before enrollment in this study. The blood flow in the analyzed hypoperfused regions was 84% (interquartile range [IQR], 66-90; P , .01) of the blood flow in the contralateral side of the brain. The median MTT was 135% (IQR 115-202; P , .01) of the time in the contralateral side.
Amyloid and tau deposition
To study whether the reduced blood flow would result in deposition of b-amyloid or tau, we assessed the retention of 18 F-Flutemetamol in all participants (n 5 11) and of 18 F-AV-1451 in a subset of subjects (n 5 5).
We found no effect on regional amyloid or tau deposition in the hypoperfused versus more normally perfused regions in the brain. The median Fig. 1C and  1D) . Two subjects had bilateral abnormal neocortical 18 FFlutemetamol uptake (composite score .1.42, Fig. 2D and Supplementary Fig. 1E ), but no asymmetry was detected in these cases.
We next correlated the ratio of the 18 F-Flutemetamol cortex (Ctx)/white matter (Wm) ratios (i.e., (Ctx Hypo / Wm Hypo )/(Ctx Normal /Wm Normal )) to the blood flow measurements (rCBF, MTT). We found no significant correlation between these two measures, again indicating that a more severe blood flow reduction is not coupled to increased b-amyloid deposition (Fig. 1E shows the rCBF data). Further, correlating the ratio above to time with arterial occlusion did not result in a significant correlation, indicating that an increased time with an arterial occlusion is not associated to an increased amyloid deposition in the affected areas (Fig. 1F) . We further compared the 18 F-Flutemetamol PET retention in the hypoperfused and contralateral cortex in composite regions supplied by the MCA. No changes in PET retention were seen between the hypoperfused and the normally perfused hemisphere in these larger regions (data not shown).
Discussion
Several studies have indicated that cerebral hypoperfusion increases amyloid deposition in animals [6] [7] [8] 10] , and vascular pathology has been proposed as an early causative event in the development of AD [9, 16, 17] . Using a multimodal imaging approach to assess the effects of cerebral hypoperfusion on b-amyloid deposition in the brain, we studied 11 patients with large vessel occlusion or stenosis resulting in a chronic unilateral hypoperfusion of the brain. We hypothesized that the brain regions with a reduction in cerebral perfusion would show an increased b-amyloid deposition. In contrast to our initial hypothesis, and to the results from animal studies [6, 8] , we found that hypoperfusion did not result in increased b-amyloid deposition compared with regions with a more normal perfusion. To account for the possibility that a decreased perfusion results in a reduced delivery of 18 FFlutemetamol, we compared ratios of cortex SUVRs divided by SUVRs in the underlying white matter with the assumption that white matter would be equally affected by a reduced delivery. The ratios again showed no difference 244  245  246  247  248  249  250  251  252  253  254  255  256  257  258  259  260  261  262  263  264  265  266  267  268  269  270  271  272  273  274  275  276  277  278  279  280  281  282  283  284  285  286  287  288  289  290  291  292  293  294  295  296  297  298  299  300  301  302  303  304  305  306  307  308  309  310   311  312  313  314  315  316  317  318  319  320  321  322  323  324  325  326  327  328  329  330  331  332  333  334  335  336  337  338  339  340  341  342  343  344  345  346  347  348  349  350  351  352  353  354  355  356  357  358  359  360  361  362  363  364  365  366  367  368  369  370  371  372  373  374  375 376 445  446  447  448  449  450  451  452  453  454  455  456  457  458  459  460  461  462  463  464  465  466  467  468  469  470  471  472  473  474  475  476  477  478  479  480  481  482  483  484  485  486  487  488  489  490  491  492  493  494  495  496  497  498  499  500  501  502  503  504  505  506  507  508  509  510  511 between hypoperfused and control regions. Nor did we find any differences in AV-1451 uptake indicating no effect of hypoperfusion on tau deposition. We further correlated the 18 F-Flutemetamol SUVRs to time with cerebral hypoperfusion or to the degree of hypoperfusion but found no effect of these measures on b-amyloid deposition.
Alterations in cerebral blood flow autoregulation [25] and reduction in cerebral blood flow have been detected in patients with advanced heart failure [26] . In line with the data presented here, a recent large Danish epidemiological study of 324,000 patients with heart failure and 1.6 million controls did not find an increased risk of developing AD in patients with heart failure, in sharp contrast to a clearly increased risk of developing vascular dementia [27] . As a supplemental analysis, we therefore studied amyloid PET positivity in patients with orthostatic hypotension compared with nonorthostatic patients in a separate cohort (the Bio-FINDER cohort, n 5 361 nondemented participants) but found no differences between the groups (see Supplementary Material for details). 512  513  514  515  516  517  518  519  520  521  522  523  524  525  526  527  528  529  530  531  532  533  534  535  536  537  538  539  540  541  542  543  544  545  546  547  548  549  550  551  552  553  554  555  556  557  558  559  560  561  562  563  564  565  566  567  568  569  570  571  572  573  574  575  576  577  578   579  580  581  582  583  584  585  586  587  588  589  590  591  592 593 594
It could be argued that the patients included in the study are too young to develop b-amyloid aggregation (median age 69 years). However, at this age, b-amyloid aggregation is getting increasingly more common and is present in approximately 20% of controls of similar age in our parallel BioFINDER study. We believe that if the subjects enrolled in the study would have had an increased propensity to aggregate b-amyloid, we should have detected this. Further, in the two cases with abnormal 18 F-Flutemetamol retention in the study, no asymmetry was detected. It could also be argued that the time with hypoperfusion is not enough for accumulation of b-amyloid. Animal data however seem to indicate rapid changes in response to hypoperfusion [6] , and one of the participants in this study had had an occlusion for more than 20 years without evidence of increased b-amyloid accumulation. Moreover, the subject with the highest SUVRs for 18 FFlutemetamol was diagnosed with an occlusion 22 months before the time of the 18 F-Flutemetamol PET scan. This subject had an 85% stenosis already, 15 years before the diagnosis of an occlusion, and has thus been accumulating b-amyloid, resulting in an abnormal amyloid PET, but without evidence of increased aggregation in the hypoperfused parts of the brain.
Our results indicate that cerebral hypoperfusion caused by large vessel occlusion due to arteriosclerosis does not induce accumulation of b-amyloid. However, this does not entirely exclude the possibility that an altered blood flow supply of nutrients due to pathology in small-vessel disease may affect b-amyloid turnover. Longstanding hypertension induces gradual thickening of small-medium sized cerebral vessels [28] , and hypertonia in midlife has been associated to an increase in white matter lesions and increased risk of developing dementia [29, 30] . Our study does not address whether alterations in cerebral small-vessel pathology may contribute to amyloid pathology. It should also be noted that using 18 F-Flutemetamol we can not exclude the possibility that there may be an increase in the levels of soluble b-amyloid in the hypoperfused regions.
Although we do not find any evidence that cerebral hypoperfusion caused by large vessel disease increases b-amyloid deposition, it is important to treat cardiovascular risk factors in the elderly population to lower the risk of vascular dementia and to reduce the additive effects of small-vessel pathology in AD.
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